Clinical Trials Directory

Trials / Completed

CompletedNCT03544606

Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
160 (actual)
Sponsor
ahmed nagy shaker ramadan · Academic / Other
Sex
Female
Age
20 Years – 35 Years
Healthy volunteers
Not accepted

Summary

The study aims to evaluate and assess the effectiveness and safety of vaginal administration of isosorbide mono nitrate (IMN) to induce cervical ripening and shorten the interval time between induction and delivery in women undergoing induction of labor. Research Hypothesis: In women undergoing induction of labor, vaginal administration of isosorbide mono nitrate (IMN) is effective to induce cervical ripening and shorten the interval time between induction and delivery. Research Questions: Does vaginal administration of isosorbide mono nitrate (IMN) induce cervical ripening and shorten the interval time between induction and delivery in women undergoing induction of labor?

Detailed description

* Type of Study : Prospective double blind randomized controlled clinical trial. * Study Setting : This study will be conducted in Kafr Elsheikh University maternity hospital. * Study Period : Expected 6 months from December 2023 to June 2024. * Study Population : Patients will be recruited in this study those attending labor ward at Kafr Elsheikh hospital for induction of labor at term or post-term with unripe cervix (Bishop Score ˂ 6).

Conditions

Interventions

TypeNameDescription
DRUGisosorbide mononitrate40 mg tablet of intra-vaginal IMN (Effox; MINAPHARMA, Cairo, Egypt) will be placed into the posterior fornix of the vagina, through a digital vaginal examination, every 4 h for a maximum of four doses.
DRUGPlacebosIn placebo group (group 2) 40 mg intra-vaginal pyridoxine placebos every 4 h for a maximum of four doses will be given

Timeline

Start date
2023-12-01
Primary completion
2024-06-15
Completion
2024-06-30
First posted
2018-06-04
Last updated
2024-08-22

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03544606. Inclusion in this directory is not an endorsement.